Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MolecularMD, a cancer drug company with expertise in analyzing tumor-related genetic mutations, has entered into an agreement with Breakthrough Therapeutics, to monitor residual disease levels in patients in clinical trials of their lead peptide vaccine, Ablvax.
Subscribe to our email newsletter
Ablvax is a therapeutic vaccine currently being evaluated as a treatment for patients with resistant chronic myeloid leukemia (CML).
Under terms of the agreement, MolecularMD will perform molecular diagnostic tests on all patients participating in the company’s ongoing trial to assess whether the disease is in remission.
The multicenter trial plans to enroll a total of 60 patients of which all will be evaluated by MolecularMD.
“We understand that the approach being studied by Abvlax offers the greatest opportunity for long-term remission for patients with CML. The ability to reliably and consistently measure molecular evidence of CML will be a key factor to interpreting the benefit of Ablvax,” noted Dr Brian Druker, scientific founder of MolecularMD.
“We are confident that their experience will be of great help in analyzing response patterns for our patients,” commented Rosemary Mazanet, CEO, Breakthrough Therapeutics.